Saturday 17 October 2026
Export RGNT’s income statement to Excel — free account
Regentis Biomaterials Ltd.
RGNT Healthcare Medical Instruments & Supplies
1.49
0.06
−3.87%
Follow RGNT
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 5.75 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 7.70 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 7 | 7 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | — | (4) | 5 | (14) | |||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | — | (4) | 5 | (14) | |||||
| Depreciation | — | — | — | — | — | — | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | — | (23.81) | 1.72 | (24.16) | |||||
| Cash flow | — | — | — | — | — | — | — | (7.03) | (0.23) | (2.43) | |||||
| Capex | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | — | — | — | (7.03) | (0.23) | (2.43) | |||||
| Book value | — | — | — | — | — | — | — | (264.58) | (14.86) | 8.37 | |||||
| Shares, m | — | — | — | — | — | — | — | 0 | 3 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (1) | (1) | (1) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | — | — | — | (1) | (1) | (1) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | (3) | (6) | 5 | ||||
| Total debt | — | — | — | — | — | — | — | 8 | 5 | 1 | |||||
| Net debt | — | — | — | — | — | — | — | 7 | 5 | (6) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | (46) | (41) | 5 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | 1,128.98 | (338.07) | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | (10.93) | 75.31 | |||||
Negative figures in brackets.
Charts ten years each
Regentis Biomaterials Ltd. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MLSS Milestone Scientific, Inc. | $29.6M | — (loss-making) | — (loss-making) | +22.27% (above 0%: growing) | n/m | +66.68% (above 0%: growing) | 67.24% | (37.37%) | Compare |
| RVP Retractable Technologies, Inc. | $17.6M | — (loss-making) | 11.1× | −31.07% (below 0%: shrinking) | n/m | +56.67% (above 0%: growing) | 2.65% | (71.46%) | Compare |
| BNGO Bionano Genomics, Inc. | $16.1M | — (loss-making) | — (loss-making) | +21.36% (above 0%: growing) | n/m | −33.93% (below 0%: shrinking) | 52.80% | (88.34%) | Compare |
| NXGL NexGel, Inc. | $15.9M | — (loss-making) | — (loss-making) | +27.81% (above 0%: growing) | n/m | −432.32% (below 0%: shrinking) | 30.09% | (67.96%) | Compare |
| FEMY Femasys Inc. | $14.5M | — (loss-making) | — (loss-making) | −18.93% (below 0%: shrinking) | n/m | +11.29% (above 0%: growing) | 57.08% | (1,526.79%) | Compare |
| CUPR Cuprina Holdings (Cayman) Limited | $11.5M | — | — | — | — | — | — | — | Compare |
| RGNT Regentis Biomaterials Ltd. | $10.9M | — | — | — | — | −132.79% (below 0%: shrinking) | — | — | |
| LUCY Innovative Eyewear, Inc. | $7.3M | — (loss-making) | — | +74.46% (above 0%: growing) | n/m | +9.61% (above 0%: growing) | 24.00% | (168.73%) | Compare |
| MHUAF Meihua International Medical Technologies Co., Ltd. | $4.3M | — | — | — | — | −61.55% (below 0%: shrinking) | 35.48% | 0.00% | Compare |
| Median of peers | $15.2M | — | — | +21.82% | — | +9.61% | 35.48% | (71.46%) |
Regentis Biomaterials Ltd. (RGNT) key facts
- Concern: Regentis Biomaterials Ltd. reported a net loss of $13.6 million, or a loss of $24.16 per share, for fiscal 2025.
- Regentis Biomaterials Ltd. (RGNT) is a Medical Instruments & Supplies company in the Healthcare sector, listed on NYSE American.
- As of October 16, 2026, RGNT traded at $1.49, a market capitalization of $10.9 million.
- Return on equity was 75.3% and debt-to-equity 0.00.